Overview

A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

Status:
NOT_YET_RECRUITING

Trial end date:
2027-09-17

Target enrollment:

Participant gender:

Summary

This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia

Phase:

PHASE3

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical

Treatments:

Dutasteride